Prothena Corp Public (PRTA) Accumulated Expenses (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly Accumulated Expenses of $8.6 million for Q1 2026, down 35.47% quarter-over-quarter from $13.3 million in Q4 2025.
Prothena Corp Public (PRTA) Accumulated Expenses (2012 - 2026) Analysis & Trends
Prothena Corp Public's Accumulated Expenses history runs 15 years deep, the most recent figure standing at $8.6 million for Q1 2026.
- In Q1 2026, Accumulated Expenses changed N/A year-over-year to $8.6 million; the TTM figure through Mar 2026 stood at $8.6 million (changed N/A YoY), while the FY2025 annual figure was $13.3 million, changed N/A from the prior year.
- Accumulated Expenses for Q1 2026 stood at $8.6 million, down from $13.3 million in the prior quarter.
- The five-year high for Accumulated Expenses was $30.3 million in Q2 2025, with the low at $6.7 million in Q1 2022.
- The 5-year median for Accumulated Expenses is $14.2 million (2023), against an average of $14.5 million.
- The sharpest annual moves came in 2022 and 2024: Accumulated Expenses jumped 118.12% in 2022, then plunged 42.57% in 2024.
- Prothena Corp Public's Accumulated Expenses stood at $10.8 million in 2022, then soared by 36.41% to $14.7 million in 2023, then fell by 29.77% to $10.3 million in 2024, then gained by 28.66% to $13.3 million in 2025, then slumped by 35.47% to $8.6 million in 2026.
- Business Quant data shows PRTA's Accumulated Expenses at $8.6 million in Q1 2026, $13.3 million in Q4 2025, and $17.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 550,000.00 |
| Mar 31, 2026 | 8.59 Mn |
| Dec 31, 2025 | 13.30 Mn |
| Sep 30, 2025 | 17.61 Mn |
| Jun 30, 2025 | 30.33 Mn |
| Sep 30, 2024 | 10.34 Mn |
| Jun 30, 2024 | 15.93 Mn |
| Mar 31, 2024 | 17.34 Mn |
| Dec 31, 2023 | 14.72 Mn |
| Sep 30, 2023 | 18.00 Mn |
| Jun 30, 2023 | 18.93 Mn |
| Mar 31, 2023 | 14.16 Mn |
| Dec 31, 2022 | 10.79 Mn |
| Sep 30, 2022 | 11.59 Mn |
| Jun 30, 2022 | 9.19 Mn |
| Mar 31, 2022 | 6.66 Mn |
| Dec 31, 2021 | 6.35 Mn |
| Sep 30, 2021 | 5.32 Mn |
| Jun 30, 2021 | 8.38 Mn |
| Mar 31, 2021 | 9.36 Mn |